Mark Messmer

This resolution recognizes the important role of women in agriculture as producers, educators, leaders, mentors, and more.

This resolution supports the designation of National Agriculture Day.

**Build the Wall Act of 2025** This bill establishes the Southern Border Wall Construction Fund to be used by the Department of Homeland Security to construct and maintain physical barriers along the U.S.-Mexico border. All unobligated amounts in the Coronavirus State and Local Fiscal Recovery Funds must be immediately deposited in the Southern Border Wall Construction Fund.

**Stop Illegal Reentry Act** This bill increases criminal penalties for certain non-U.S. nationals (*aliens* under federal law) who illegally reenter the United States after removal or exclusion. Generally, an individual who had been denied entry into or removed from the United States and who later enters or attempts to enter the United States without prior approval from the Department of Homeland Security shall be fined, imprisoned for up to five years, or both. Current law requires a fine, imprisonment for up to two years, or both, for such an individual. An individual who had been denied entry or removed three or more times and who later enters or attempts to enter the United States shall be fined, imprisoned for up to 10 years, or both. An individual who was convicted of an aggravated felony or convicted at least two times before removal or departure and who subsequently enters or tries to enter the United States shall be imprisoned at least 5 years and for up to 20 years and may also be fined. Currently, there is no minimum term of imprisonment for an individual who reenters after a conviction for an aggravated felony, and there are no criminal penalties for a reentering individual who had been convicted at least two times (other than the penalties for illegal reentry generally).

**China Exchange Rate Transparency Act of 2023** This bill requires the U.S. Executive Director at the International Monetary Fund (IMF) to use the voice and vote of the United States to advocate for increased exchange rate transparency from China. Some areas of focus for this advocacy are (1) Chinese exchange rate arrangements, including any indirect foreign exchange market intervention through Chinese financial institutions or state-owned enterprises; (2) enhanced multilateral and bilateral surveillance by the IMF; and (3) stronger consideration of China's performance as a responsible stakeholder in the international monetary system when evaluating quota and voting shares at the IMF. The requirements of the bill expire seven years and 30 days after the date of the bill's enactment or earlier if China meets certain conditions regarding its exchange rate policies.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.